4d Pharma PLC Virtual KOL Event SITC Data
05 Novembre 2020 - 1:00PM
RNS Non-Regulatory
TIDMDDDD
4d Pharma PLC
05 November 2020
4D Pharma to Host Virtual KOL Event Reviewing New Data Presented
at the Society for Immunotherapy of Cancer Annual Meeting 2020 from
Live Biotherapeutic MRx0518 Clinical Programs
Leeds, UK, November 5, 2020 , - 4D pharma plc (AIM: DDDD), a
pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs) - a novel class of drug derived from
the microbiome, today announces that it will host a virtual Key
Opinion Leader (KOL) event to review data presented from two
ongoing clinical trials of MRx0518, the Company's lead
immuno-oncology single strain Live Biotherapeutic, as both a
neoadjuvant monotherapy and combination therapy in patients
refractory to checkpoint inhibitors at the Society for
Immunotherapy of Cancer (SITC) Annual Meeting 2020. The event will
take place on Wednesday, November 11, 2020 at 1:00pm GMT (8:00am
ET).
The event will feature presentations from 4D pharma management
and KOLs, Dr Mark P Lythgoe, Academic Clinical Fellow in Medical
Oncology and Pharmacist at Imperial College London, and Dr Shubham
Pant, Associate Professor Department of Investigational Cancer
Therapeutics and Department of Gastrointestinal Medical Oncology at
the University of Texas MD Anderson Cancer Center.
A live webcast of the event will be available on the Reports and
Presentations section of the 4D Pharma website at
www.4dpharmaplc.com . To access the call, please dial
1-877-270-2148 (United States) or 1-412-902-6510 (international)
and reference the 4D pharma conference call to join. A replay of
the webcast and accompanying slides will be available on the 4D
pharma website following the event.
About 4D pharma
Founded in February 2014, 4D pharma is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx(R), that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programmes,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumours, a Phase I
study of MRx0518 in patients with pancreatic cancer, a Phase I/II
study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in
patients hospitalised with COVID-19, and Blautix(R) in Irritable
Bowel Syndrome (IBS) which has completed a successful Phase II
trial. Preclinical-stage programmes include candidates for CNS
disease such as Parkinson's disease and other neurodegenerative
conditions. The Company has a research collaboration with MSD, a
tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to
discover and develop Live Biotherapeutics for vaccines.
In October 2020 4D pharma announced its intention to merge with
Longevity Acquisition Corporation (NASDAQ: LOAC), a special purpose
acquisition company (SPAC), and seek a NASDAQ listing. The merger
is expected to be completed and the NASDAQ listing of 4D pharma
American Depositary Shares (ADSs) under the ticker symbol 'LBPS' is
currently expected to become effective in early 2021, subject to
approval of 4D Shareholders and Longevity Shareholders, and the SEC
review process.
For more information, refer to https://www.4dpharmaplc.com .
Contact Information:
4D Pharma
Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130
Investor Relations: ir@4dpharmaplc.com
Investor Relations
Julie Seidel, Stern Investor Relations, Inc. +1-212-362-1200
Julie.seidel@sternir.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496
3000
Philip Davies / Justin McKeegan / Iqra Amin (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson / Phil Walker
Image Box Communications
Neil Hunter / Michelle Boxall +44 (0)20 8943 4685
neil@ibcomms.agency / michelle@ibcomms.agency
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABABLTMTTMMPM
(END) Dow Jones Newswires
November 05, 2020 07:00 ET (12:00 GMT)
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Apr 2023 a Apr 2024